Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Trailhead Biosystems Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 actions are assigned to 4 distinct examiners, ensuring that each application is being reviewed by a different individual. While the examiners are all unique, they are situated within only 2 distinct art units, which implies that the pending matters are concentrated in two specific technical sub-sectors. The busiest examiner, STAVROU, CONSTANTINA E, holds 1 pending office action.
With 4 pending office actions and 4 distinct examiners, the busiest examiner pending count of 1 confirms that the workload is distributed across all 4 examiners. This structure, featuring 4 distinct examiners across 2 distinct art units, suggests that multiple examiners are likely operating within the same art unit. Practitioners should coordinate their prosecution strategy to account for the standards of the 2 distinct art units while addressing the individual preferences of the 4 examiners. This balance of examiner diversity and art unit concentration is a key feature of the current Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 42.4% | +35.6% |
| TAKENAKA, RISA | 1 | 26.1% | +100.0% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 31d overdue |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 31d overdue |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 10d overdue |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 14d |
| 18199415 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18199415 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | STAVROU, CONSTANTINA E | 1632 | §112 | Final Rejection | — | Pending | May 19, 2023 |
| 18071388 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TAKENAKA, RISA | 1632 | §103 | Final Rejection | 31d overdue | Pending | Nov 29, 2022 |
| 17896781 | Methods and Compositions for Generating Human Forebrain Neural Progenitor Cells and for Maturation Thereof to Parvalbumin+ Interneurons | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | 14d | Pending | Aug 26, 2022 |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 10d overdue | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrailhead Biosystems Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Constantina E Stavrou has the most, with 1 of Trailhead Biosystems Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
